Lorvotuzumab Mertansine
Merkel Cell Carcinoma
ImmunoGen, Inc.antibody_drug_conjugatePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
46 Active assets in the Merkel Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Merck Sharp & Dohme LLC | Phase 3 | BB |
Cyclophosphamide Merck Sharp & Dohme LLC | Phase 2/3 | BB |
Ifx-Hu2.0 TuHURA Biosciences, Inc. | Phase 2/3 | B |
Durvalumab Ariceum Therapeutics GmbH | Phase 2 | B |
Nivolumab Fred Hutchinson Cancer Center | Phase 2 | B |
View all 50 →
Same molecule, other indications
Lorvotuzumab Mertansine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →